tirzepatide phase 3 mash in Type 2 Diabetes: Pathophysiology, Diagnosis, and Therapeutic Management—A Narrative Review EBM BLS: Tirzepatide Leads to

Obstructive Sleep Apnea Market In 2023, the total Obstructive Sleep Apnea Diagnosed Prevalence was approximately 25,670 thousand in the 7MM, which is further expected to increase by 2034

Specifically, NICE suggests considering a DPP-4 inhibitor as a second agent when: The patient has a high risk of hypoglycaemia (making sulfonylureas less suitable) Weight management is a concern and a sulfonylurea's weight-gaining effects are undesirable An SGLT-2 inhibitor is contraindicated or not tolerated NICE NG28 recommends that in patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, an SGLT-2 inhibitor should generally be prioritised often alongside or instead of metformin due to its organ-protective benefits

The mGIPR-Ab/P1 treatment did not reduce epididymal weight (Fig

The risk of the degenerative bone disease osteoporosis rose by about 30 percent percent, and the risk of the bone softening condition osteomalacia occurred about twice as often among people on the drugs

Forced swimming test Behavioural despair test in which the degree to which a rodent swims when placed in a cylinder filled with water from which it cannot escape is taken as a measure of antidepressant activity

In technical terms, it is a glucagon-like peptide-1 receptor agonist (GLP-1 RA)